BRAF and neoplasm: Studies examining the effects of sorafenib on sorafenib-resistant cell lines transfected with BRAF genes containing gatekeeper mutations indicated that the mutant B-Raf signaling was resistant to sorafenib, but sorafenib still inhibited tumor growth driven by the mutant B-Raf protein.